Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William R Wilson

Showing results (31-40 of 125) with videos related to

Pageof 13
Sort By:
Radiation Research|November 28, 2002
Pathways of reductive fragmentation of heterocyclic nitroarylmethyl quaternary ammonium prodrugs of mechlorethamineAngela G Kriste, Moana Tercel, Robert F Anderson, et al.
Cancer Research|October 3, 2003
Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study in HT29 multicellular layer culturesKevin O Hicks, Frederik B Pruijn, Joanna R Sturman, et al.
Cancer Letters|June 1, 2016
Growth hormone receptor antagonism suppresses tumour regrowth after radiotherapy in an endometrial cancer xenograft modelAngharad Evans, Stephen M F Jamieson, Dong-Xu Liu, et al.
Journal of Medicinal Chemistry|May 30, 2003
Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductaseMichael P Hay, Graham J Atwell, William R Wilson, et al.
Chemical Research in Toxicology|February 1, 2017
DNA Adduct Profiles Predict in Vitro Cell Viability after Treatment with the Experimental Anticancer Prodrug PR104AAlessia Stornetta, Peter W Villalta, Frederike Gossner, et al.
Journal of Medicinal Chemistry|December 4, 2003
Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapyMichael P Hay, Robert F Anderson, Dianne M Ferry, et al.
Journal of Pharmaceutical Sciences|September 13, 2014
Photodegradation of the benzotriazine 1,4-Di-N-oxide hypoxia-activated prodrug SN30000 in aqueous solutionYongchuan Gu, Jagdish K Jaiswal, Jingli Wang, et al.
Cancer Biology & Therapy|May 28, 2019
Schedule-dependent potentiation of chemotherapy drugs by the hypoxia-activated prodrug SN30000Xinjian Mao, Sarah McManaway, Jagdish K Jaiswal, et al.
Molecular Cancer Therapeutics|September 7, 2014
Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancerFrancis W Hunter, Huai-Ling Hsu, Jiechuang Su, et al.
Chemical Research in Toxicology|November 17, 2011
DNA strand cleavage by the phenazine di-N-oxide natural product myxin under both aerobic and anaerobic conditionsGoutam Chowdhury, Ujjal Sarkar, Susan Pullen, et al.
Pageof 13

Showing results (31-40 of 125) with videos related to

Sort By:
Pageof 13
Radiation Research|November 28, 2002
Pathways of reductive fragmentation of heterocyclic nitroarylmethyl quaternary ammonium prodrugs of mechlorethamineAngela G Kriste, Moana Tercel, Robert F Anderson, et al.
Cancer Research|October 3, 2003
Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study in HT29 multicellular layer culturesKevin O Hicks, Frederik B Pruijn, Joanna R Sturman, et al.
Cancer Letters|June 1, 2016
Growth hormone receptor antagonism suppresses tumour regrowth after radiotherapy in an endometrial cancer xenograft modelAngharad Evans, Stephen M F Jamieson, Dong-Xu Liu, et al.
Journal of Medicinal Chemistry|May 30, 2003
Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductaseMichael P Hay, Graham J Atwell, William R Wilson, et al.
Chemical Research in Toxicology|February 1, 2017
DNA Adduct Profiles Predict in Vitro Cell Viability after Treatment with the Experimental Anticancer Prodrug PR104AAlessia Stornetta, Peter W Villalta, Frederike Gossner, et al.
Journal of Medicinal Chemistry|December 4, 2003
Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapyMichael P Hay, Robert F Anderson, Dianne M Ferry, et al.
Journal of Pharmaceutical Sciences|September 13, 2014
Photodegradation of the benzotriazine 1,4-Di-N-oxide hypoxia-activated prodrug SN30000 in aqueous solutionYongchuan Gu, Jagdish K Jaiswal, Jingli Wang, et al.
Cancer Biology & Therapy|May 28, 2019
Schedule-dependent potentiation of chemotherapy drugs by the hypoxia-activated prodrug SN30000Xinjian Mao, Sarah McManaway, Jagdish K Jaiswal, et al.
Molecular Cancer Therapeutics|September 7, 2014
Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancerFrancis W Hunter, Huai-Ling Hsu, Jiechuang Su, et al.
Chemical Research in Toxicology|November 17, 2011
DNA strand cleavage by the phenazine di-N-oxide natural product myxin under both aerobic and anaerobic conditionsGoutam Chowdhury, Ujjal Sarkar, Susan Pullen, et al.
Pageof 13